SCHEMBL4350844

SCHEMBL4350844

COc1ccc(Oc2cccc(CNc3cc(Cl)cc(Cl)c3O)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 2/20 0.55
MAPT P10636 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ACLY P53396 1/20 0.47
HDAC8 Q9BY41 2/20 0.46
ABCB1 P08183 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MMP13 P45452 1/20 0.43
ACP1 P24666 1/20 0.43
STK39 Q9UEW8 2/20 0.42
FFAR1 O14842 1/20 0.42
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4351954 0.92 STK39 (0.45) HTTSMN1; SMN2KDM4EALDH1A1ACLY
SCHEMBL4356091 0.90 FFAR1 (0.49) HTTSMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL4354025 0.88 KDM4E (0.54) HTTSMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL4354087 0.88 ACLY (0.43) HTTSMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL4351985 0.84 MAPT (0.58) HTTSMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL4343612 0.84 ALDH1A1 (0.50) HTTSMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL4342411 0.81 FFAR1 (0.45) HTTSMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL4356057 0.79 ALDH1A1 (0.52) HTTSMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL4353549 0.79 ALDH1A1 (0.54) HTTSMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL4350104 0.79 MEN1 (0.60) HTTSMN1; SMN2KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 HTT 3824/4885SMN1; SMN2 1791/4885KDM4E 2662/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 HTT 3995/4885SMN1; SMN2 3250/4885KDM4E 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.